CAMP4 Therapeutics said Monday it is targeting proceeds of up to $80 million in its planned initial public offering of 5 million shares priced between $14 and $16 each.
The company said that upon completion of the IPO, it expects to have around 17.7 million shares outstanding.
CAMP4 is seeking to list its shares in the Nasdaq Global Market under the symbol "CAMP."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.